File(s) under permanent embargo
Incretin-based therapies
The number of Australians with type 2 diabetes mellitus (T2DM) has tripled since 1981 and continues to increase. It is projected that 1.6 million Australians will have type 2 diabetes by 2030. Because T2DM frequently co-exists with excess weight, hypertension and dyslipidaemia, health professionals involved in the management of diabetes should focus on blood pressure management, cholesterol lowering and consider the use of lowdose aspirin for primary prevention (although this is now contentious) as means of reducing cardiovascular risk, in addition to targeting glycaemic control
History
Publication title
Australian PharmacistVolume
29Issue
6Pagination
508-513ISSN
0728-4632Department/School
School of Pharmacy and PharmacologyPublisher
Pharmaceutical Society of AustraliaPlace of publication
AustraliaRights statement
Copyright © 2010 Pharmaceutical Society of AustraliaRepository Status
- Restricted